News headlines about Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharmaceutical Holding Co earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.1783360994853 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Several brokerages recently weighed in on BHVN. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Needham & Company LLC began coverage on Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued a “buy” rating and a $30.00 target price on the stock. Morgan Stanley began coverage on Biohaven Pharmaceutical Holding Co in a research report on Wednesday, May 31st. They issued an “overweight” rating on the stock. Piper Jaffray Companies began coverage on Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued an “overweight” rating and a $21.00 target price on the stock. Finally, Barclays PLC began coverage on Biohaven Pharmaceutical Holding Co in a research report on Tuesday, May 30th. They issued an “overweight” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co presently has an average rating of “Buy” and an average target price of $31.75.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) traded down 3.54% on Wednesday, hitting $35.15. The company had a trading volume of 315,702 shares. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $36.55. The company’s market cap is $1.26 billion. The company has a 50 day moving average of $25.97 and a 200-day moving average of $24.54.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/biohaven-pharmaceutical-holding-co-bhvn-getting-somewhat-favorable-press-coverage-study-finds/1532465.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.